These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 33745288)

  • 21. Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.
    Lee JY; Ma HI; Ferreira JJ; Rocha JF; Sung YH; Song IU; Ahn TB; Kwon DY; Cheon SM; Kim JM; Lee CS; Lee PH; Park JH; Lee JH; Park MY; Kim SJ; Baik JS; Choi SM; Shin HW; Lee HW; Kang SY; Jeon B
    Mov Disord Clin Pract; 2024 Jun; 11(6):655-665. PubMed ID: 38594812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
    St Onge E; Vanderhoof M; Miller S
    Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
    Svetel M; Tomić A; Kresojević N; Kostić V
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
    Linazasoro-Cristóbal G; López Del Val LJ; García Ruiz-Espiga P; López-Manzanares L; Luquin-Piudo MR; Martínez-Castrillo JC; Mir P; Pagonabarraga-Mora J
    Rev Neurol; 2020 Jun; 70(s01):S1-S11. PubMed ID: 32515486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
    Żegleń M; Śladowska K; Kawalec P; Brzostek T
    J Comp Eff Res; 2022 Aug; 11(12):889-904. PubMed ID: 35758044
    [No Abstract]   [Full Text] [Related]  

  • 26. Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.
    Annus Á; Vécsei L
    Drug Des Devel Ther; 2017; 11():143-151. PubMed ID: 28123288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P
    Eur J Neurol; 2019 Jul; 26(7):953-960. PubMed ID: 30681754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety Profile of Opicapone in the Management of Parkinson's Disease.
    Lees A; Ferreira JJ; Rocha JF; Rascol O; Poewe W; Gama H; Soares-da-Silva P
    J Parkinsons Dis; 2019; 9(4):733-740. PubMed ID: 31498127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opicapone: A Review in Parkinson's Disease.
    Scott LJ
    CNS Drugs; 2021 Jan; 35(1):121-131. PubMed ID: 33428178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
    Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
    J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations.
    Berger AA; Robinson C; Winnick A; Izygon J; Jacob BM; Noonan MJ; Kaye AD; Kaye JS; Kaye AM; Cornett EM; Shah RJ; Viswanath O; Urits I
    Clin Drug Investig; 2022 Feb; 42(2):127-135. PubMed ID: 34935105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opicapone for the treatment of Parkinson's disease: a review.
    Feldman M; Margolesky J
    Int J Neurosci; 2023 May; 133(5):532-543. PubMed ID: 33980110
    [No Abstract]   [Full Text] [Related]  

  • 34. The preclinical discovery and development of opicapone for the treatment of Parkinson's disease.
    Ettcheto M; Busquets O; Sánchez-Lopez E; Cano A; Manzine PR; Verdaguer E; Olloquequi J; Auladell C; Folch J; Camins A
    Expert Opin Drug Discov; 2020 Sep; 15(9):993-1004. PubMed ID: 32450711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
    Wu W; Lu X; Zhang L; Hong D
    Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
    Katsaiti I; Nixon J
    J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
    Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Moreira J; Guimarães B; Rocha JF; Soares-da-Silva P
    Mov Disord; 2022 Nov; 37(11):2272-2283. PubMed ID: 36054562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease.
    Schofield C; Chaudhuri KR; Carroll C; Sharma JC; Pavese N; Evans J; Foltynie T; Reichmann H; Zurowska L; Soares-da-Silva P; Lees A
    Neurodegener Dis Manag; 2022 Apr; 12(2):77-91. PubMed ID: 35313124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial.
    Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Moreira J; Pereira A; Rocha JF; Soares-da-Silva P
    Neurol Ther; 2022 Sep; 11(3):1409-1425. PubMed ID: 35705887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.